MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- VENUS REMEDIES
- VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1%
VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1%
Wed, 12 Jun
VENUS REMEDIES has announced its results for the quarter ended March 2019. Here is a detailed performance review of the same:
VENUS REMEDIES Quarterly Financials
| No. of Mths Qtr. Ending | 3 Mar-18* | 3 Dec-18* | 3 Mar-19* | QoQ Change | YoY Change | |
|---|---|---|---|---|---|---|
| Net Sales | Rs m | 932 | 691 | 864 | 25.1% | -7.3% |
| Other income | Rs m | 3 | 5 | 38 | 714.4% | 1036.2% |
| Turnover | Rs m | 935 | 695 | 902 | 29.7% | -3.6% |
| Expenses | Rs m | 838 | 643 | 835 | 29.8% | -0.4% |
| Gross profit | Rs m | 94 | 47 | -61 | -227.8% | -164.6% |
| Depreciation | Rs m | 62 | 83 | 83 | 0.0% | 34.1% |
| Interest | Rs m | 98 | 94 | 0 | -100.0% | -100.0% |
| Profit before tax | Rs m | -62 | -125 | -105 | ||
| Tax | Rs m | 32 | -6 | -1 | -103.3% | |
| Profit after tax | Rs m | -94 | -119 | -104 | ||
| Gross profit margin | % | 10.1 | 6.9 | -7.0 | ||
| Effective tax rate | % | -50.9 | 4.4 | 1.0 | ||
| Net profit margin | % | -10.0 | -17.2 | -11.6 |
Interim results exclude extraordinary / exceptional items
Year-on-Year Performance:
- The company's operating income during the quarter fell 7.3% on a year-on-year (YoY) basis. The expenses were down by 0.4% YoY during the same period.
- The company's operating profit declined by 164.6% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 7.0% in 4QFY19 as against 10.1% in 4QFY18.
- Depreciation charges increased by 34.1% and finance costs declined by 100.0% YoY, respectively.
- Other income increased by 1036.2% YoY during the quarter.
- Net profit for the quarter declined by 11.1% YoY. Net profit margins during the quarter declined from -10.0% in 4QFY18 to -11.6% in 4QFY19.
Quarter-on-Quarter Performance:
- The company's operating income during the quarter grew 25.1% on a quarter-on-quarter (QoQ) basis. The expenses were up by 29.8% QoQ during the same period.
- The company's operating profit declined by 227.8% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 7.0% in 4QFY19 as against 6.9% in 3QFY18.
- Net profit for the quarter increased by 12.7% QoQ, while net profit margins increased from -17.1% in 3QFY18 to -11.6% in 4QFY19.
To see how VENUS REMEDIES has performed over the last eight quarters, please visit here.
VENUS REMEDIES Share Price Performance
Over the last one year, VENUS REMEDIES share price has moved up from Rs 57.1 to Rs 27.4, registering a Loss of Rs 29.7 or around 52.0%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,132.3 (up 0.0%). Over the last one year it has moved down from 13,755.6 to 13,132.3, a gain of 623 points (down 4.5%).
Overall, the S&P BSE SENSEX is up 12.2% over the year.
Current Valuations
At the current price of Rs 27.4, the price to book value (P/BV) ratio of VENUS REMEDIES stands at 0.1 times.
|
| |
Related Views on News
VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)
Feb 22, 2019 | Updated on Feb 22, 2019For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)
Dec 21, 2018 | Updated on Dec 21, 2018Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.
VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)
Nov 23, 2018 | Updated on Nov 23, 2018For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)
Oct 14, 2019This is once in a decade opportunity to make a killing from smallcap rebound.
Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)
Oct 7, 2019Here's what every individual investor must know about Yes Bank...
Two Stocks to Buy in the Great Indian Festival(Profit Hunter)
Oct 11, 2019Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.
The One Stock I Like in this Market(The 5 Minute Wrapup)
Oct 10, 2019There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?
5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)
Oct 11, 2019Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.
More|
| |
VENUS REMEDIES SHARE PRICE
Oct 18, 2019 09:07 AM
TRACK VENUS REMEDIES
- Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON VENUS REMEDIES
VENUS REMEDIES 5-YR ANALYSIS
COMPARE VENUS REMEDIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster requests your view! Post a comment on "VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!